This process involves the activation of specific signaling pathways, such as transforming growth factor-beta (TGF-β), epidermal growth factor receptor (EGFR), Notch, and nuclear factor-kappa B (NF-κB), and the secretion of enzymes, such as matrix metalloproteinases (MMPs), cathepsins, serine proteases (including urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA)), hyaluronidase, and A disintegrin and metalloproteinases (ADAMs), that degrade the ECM, allowing cancer cells to invade adjacent tissues [13]. The gene discussed is PLAU; the disease is cancer.